Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Pharmacological Reviews

• Publication date

  2003-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/pr.55.1.4PMID 12615954
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic Oral Administration of CI-994: A Phase I Study

  2004cited by this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cited by this paper
• bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer

  2004cited by this paper
• Targeting the epidermal growth factor receptor

  2004cited by this paper
• Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.

  2002cited by this paper
• Factors influencing the cellular accumulation of SN-38 and camptothecin

  2002cited by this paper
• Proteomic tools for biomedicine.

  2002cited by this paper
• Novel approaches to the treatment of non-small cell lung cancer.

  2002cited by this paper
• Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

  2002cited by this paper
• Apoptosis: a guide for the perplexed.

  2002cited by this paper
• [Molecular abnormalities in lung cancer].

  2002influential reference
• Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.

  2002cited by this paper
• p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer

  2002influential reference
• Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer.

  2002cited by this paper
• The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cells.

  2002cited by this paper
• Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

  2002cited by this paper
• De Novo Ceramide Regulates the Alternative Splicing of Caspase 9 and Bcl-x in A549 Lung Adenocarcinoma Cells

  2002cited by this paper
• Proteome analysis of butyrate‐treated human colon cancer cells (HT‐29)

  2002cited by this paper
• Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

  2002cited by this paper
• Induction of MUC2 and MUC5AC Mucins by Factors of the Epidermal Growth Factor (EGF) Family Is Mediated by EGF Receptor/Ras/Raf/Extracellular Signal-regulated Kinase Cascade and Sp1*

  2002cited by this paper
• Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

  2002cited by this paper
• Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial.

  2002cited by this paper
• Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer.

  2002cited by this paper
• Characteristics of long-term survivors of untreated lung cancer.

  2002cited by this paper
• Cancer Statistics, 2002

  2002cited by this paper
• Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells

  2002cited by this paper
• Chemotherapy of non-small cell lung cancer in elderly patients.

  2002cited by this paper
• Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.

  2002cited by this paper
• Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

  2002cited by this paper
• The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.

  2002cited by this paper
• Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer.

  2002cited by this paper
• Mutational analysis of the β-tubulin gene in lung cancer

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Mutational analysis of the beta-tubulin gene in lung cancer.

  2002cited by this paper
• Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer

  2002cited by this paper
• Trimodality treatment in Stage III nonsmall cell lung carcinoma

  2002cited by this paper
• Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.

  2002influential reference
• Study of Therapy Resistance in Cancer Cells with Functional Proteome Analysis

  2002cited by this paper
• New treatment approaches for lung cancer and impact on survival.

  2002cited by this paper
• New treatment approaches for lung cancer and impact on survival

  2002cited by this paper
• Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.

  2001cited by this paper
• Clinical significance of the Rb expression in adenocarcinoma of the lung.

  2001cited by this paper
• Technetium-99m Tetrofosmin Chest Imaging Related to P-Glycoprotein Expression for Predicting the Response with Paclitaxel-Based Chemotherapy for Non-Small Cell Lung Cancer

  2001cited by this paper
• DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.

  2001cited by this paper
• Combined Expression of p53, Bcl-2, and p21WAF-1 Proteins in Lung Cancer and Premalignant Lesions: Association with Clinical Characteristics

  2001cited by this paper
• The Rb/chromatin connection and epigenetic control: opinion

  2001cited by this paper
• Proteomics. Making sense of genomic information for drug discovery.

  2001cited by this paper
• Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.

  2001cited by this paper
• Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

  2001influential reference
• Molecular genetics of small cell lung carcinoma.

  2001influential reference
• Herceptest: Her2 expression and gene amplification in non‐small cell lung cancer

  2001cited by this paper
• Identification of tumor suppressor candidate genes by physical and sequence mapping of the TSLC1 region of human chromosome 11q23.

  2001cited by this paper
• Non-small cell lung cancer with single brain metastasis: the role of surgical treatment.

  2001cited by this paper
• Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine.

  2001cited by this paper
• Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c- myc and epidermal growth factor in alveolar type II pneumocytes

  2001cited by this paper
• Towards a biological staging model for operable non-small cell lung cancer.

  2001cited by this paper
• Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.

  2001cited by this paper
• Regulation of the G2/M transition by p53

  2001cited by this paper
• Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

  2001cited by this paper
• TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer

  2001cited by this paper
• Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide

  2001cited by this paper
• Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer.

  2001cited by this paper
• Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer.

  2001cited by this paper
• Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines

  2001cited by this paper
• Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.

  2001cited by this paper
• In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype.

  2001influential reference
• p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

  2001cited by this paper
• The role of chemotherapy in early stage of non-small cell lung cancer.

  2001cited by this paper
• Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.

  2001cited by this paper
• Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer.

  2001cited by this paper
• Two‐dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: Protein pattern changes following treatment with 5′‐azycytidine

  2001cited by this paper
• MDM2: life without p53.

  2001cited by this paper
• Pharmacogenetic determinants of anti-cancer drug activity and toxicity.

  2001cited by this paper
• Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer.

  2001cited by this paper
• Clinical proteomics: personalized molecular medicine.

  2001influential reference
• Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells

  2001cited by this paper
• Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer.

  2001cited by this paper
• Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas

  2001cited by this paper
• Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells.

  2001cited by this paper
• Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.

  2001cited by this paper
• The Rb/E2F pathway and cancer.

  2001cited by this paper
• Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.

  2001cited by this paper
• Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer.

  2001cited by this paper
• Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.

  2001cited by this paper
• Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.

  2001cited by this paper
• Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.

  2001cited by this paper
• Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.

  2001cited by this paper
• Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications

  2001cited by this paper
• Proteomics--post-genomic cartography to understand gene function.

  2001cited by this paper
• Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas.

  2001influential reference
• Two consistently deleted regions within chromosome 1p32‐pter in human non–small cell lung cancer

  2001cited by this paper
• Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.

  2001cited by this paper
• Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer.

  2001cited by this paper
• Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

  2001cited by this paper
• Function of the c-Myc oncoprotein in chromatin remodeling and transcription.

  2001cited by this paper
• Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer.

  2001cited by this paper
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  2001cited by this paper
• Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.

  2001cited by this paper
• Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.

  2001cited by this paper

• Genetic polymorphisms in the mismatch repair pathway (MMR) genes contribute to hematological and gastrointestinal toxicity in North Indian lung cancer patients treated with platinum‐based chemotherapy

  2022cites this paper
• Design of 2-Phenylamino Benzothiopyrano [4,3-D] Pyrimidines Compound as an Anticancer

  2019cites this paper
• The Inhibitory Mechanism of Compound K on A549 Lung Cancer Cells through EGF Pathway:An in Silico and in Vitro Approach

  2016cites this paper
• The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non–Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy1

  2016cites this paper
• Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer

  2016cites this paper
• Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non–Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy

  2015cites this paper
• Apoptotic effect of cordycepin on A549 human lung cancer cell line

  2015cites this paper
• Lung Cancer Stem Cells and Their Therapeutic Targeting

  2015influential citation
• Melatonin potentiates cisplatin‐induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells

  2015cites this paper
• Reassessing the two-year rodent carcinogenicity bioassay: a review of the applicability to human risk and current perspectives.

  2014cites this paper
• Characterization and in vitro studies on anticancer activity of exopolymer of Bacillus thuringiensis S13

  2014cites this paper
• BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy

  2014cites this paper
• Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.

  2012cites this paper
• Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line.

  2012cites this paper
• Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy

  2012cites this paper
• Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.

  2012cites this paper
• Promoter Methylation of CDKN2A, RARβ, and RASSF1A in Non-Small Cell Lung Carcinoma: Quantitative Evaluation Using Pyrosequencing

  2012cites this paper
• The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse

  2012cites this paper
• Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.

  2012cites this paper
• Systematic analysis of genotype‐specific drug responses in cancer

  2012cites this paper
• Genomics and cancer drug resistance.

  2012cites this paper
• ATM/ATR and SMAD3 pathways contribute to 3-indole-induced G₁ arrest in cancer cells and xenograft models.

  2011cites this paper
• Korelasi Imunoekspresi Her2/Neu dan P53 dengan Respon Kemoterapi Cisplatin pada Karsinoma Paru Bukan-Sel Kecil

  2011cites this paper
• Pharmacogenomics and cancer stem cells: a changing landscape?

  2011influential citation
• Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

  2011cites this paper
• miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway.

  2011cites this paper
• Anticancer Effect of a Novel Histone Deacetylase Inhibitor in Cell Model

  2010cites this paper
• Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.

  2010cites this paper
• A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer

  2010cites this paper
• Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer

  2010cites this paper
• Profilo mutazionale degli oncogeni EGFR e KRAS in cellule di carcinoma broncogeno non-a-piccole cellule ottenute da Fine needle aspiration cytology (FNAC)

  2010cites this paper
• Association of XPD Polymorphisms with Severe Toxicity in Non–Small Cell Lung Cancer Patients in a Chinese Population

  2009cites this paper
• Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.

  2009cites this paper
• EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells

  2009cites this paper
• Proteomic analysis of multidrug‐resistance mechanisms in adriamycin‐resistant variants of DLKP, a squamous lung cancer cell line

  2009cites this paper
• Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy

  2009cites this paper
• A Novel Synthetic Indole Compound, 1,1,3-tri(3-indolyl)cyclohexane, Inhibits Microtubule Polymerization in Human Lung Cancer Cells

  2008cites this paper
• Papel de las enzimas citocromo p450 en el metabolismo de fármacos antineoplásicos: Situación actual y perspectivas terapéuticas

  2008cites this paper
• Development of taxane resistance in a panel of human lung cancer cell lines.

  2008cites this paper
• Novel 2‐step synthetic indole compound 1,1,3‐tri(3‐indolyl)cyclohexane inhibits cancer cell growth in lung cancer cells and xenograft models

  2008cites this paper
• Pharmacogenetics of Antiangiogenic Therapy

  2008cites this paper
• mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines

  2008cites this paper
• Genetic variants of miRNA sequences and non-small cell lung cancer survival.

  2008cites this paper
• Ectopic Tbx2 expression results in polyploidy and cisplatin resistance

  2008cites this paper
• [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].

  2008cites this paper
• Pharmacogenetics in oncology

  2008cites this paper
• Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores.

  2007cites this paper
• Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.

  2007influential citation
• Multimodality approach to early-stage non-small cell lung cancer.

  2007cites this paper
• Surgery and multimodality therapy for mesothelioma: E01-03

  2007cites this paper
• E09-03: Predictive markers for adjuvant treatment

  2007cites this paper
• E09-03 Adjuv ant Treatment for Resectable Lung Cancer, Tue, Sept 4, 16:00 - 17:30 Predictive markers for adjuvant treatment

  2007cites this paper
• Past, present and future of gene expression-tailored therapy for lung cancer.

  2006cites this paper
• Morphological and growth alterations in Vero cells transformed by cisplatin

  2006cites this paper
• [Pharmacogenetics and pharmacogenomics of cancers].

  2006cites this paper
• Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug

  2006cites this paper
• Taxanes in the Treatment of Non-Small Cell Lung Cancer

  2006cites this paper
• Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells

  2005cites this paper
• Asthma, the ugly duckling of lung disease proteomics?

  2005cites this paper
• Integrin alpha v beta 3-targeted imaging of lung cancer.

  2005cites this paper
• Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.

  2005cites this paper
• Molecular biology of the lung cancer

  2005cites this paper
• Analysis of DNA damage and cellular responses to platinum-based chemotherapeutic agents in 'in vitro' models of non-small cell lung cancer

  2005cites this paper
• Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genes

  2005cites this paper
• Integrin αβ3-Targeted Imaging of Lung Cancer

  2005cites this paper
• Integrin avB3–Targeted Imaging of Lung Cancer

  2005cites this paper
• Molecular mechanism of antitumor activity of taxanes in lung cancer (Review).

  2005cites this paper
• Pharmacogenetics of neoplastic diseases: new trends.

  2004cites this paper
• Pharmacogénétique et pharmacogénomique des cancers

  2004cites this paper
• Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer

  2004cites this paper
• The biology of non-small-cell lung cancer: identifying new targets for rational therapy.

  2004cites this paper
• Pharmacogenetics in Cancer Chemotherapy: Balancing Toxicity and Response

  2004cites this paper
• Pharmacogenetics.

  2004cites this paper
• Pharmacogenetic candidate genes for melanoma.

  2003cites this paper
• Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

  2003cites this paper